Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Study acronym: CONTRAC-2
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Mar 31, 2031 → Apr 30, 2031
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 30, 2026 to Nov 30, 2026
    • Primary and study completion pushed from Mar 31, 2031 to Apr 30, 2031
    • Eligibility criteria expanded, about 44 words
    • Secondary endpoints: details revised at 6 of 9 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemiplimab alongside standardized immune suppression will generate anti-tumor activity without triggering allograft rejection.
Trial Details
NCT Number NCT07715734
Lead Sponsor Washington University School of Medicine
Collaborators: Regeneron Pharmaceuticals
Conditions
(from sponsor)		 Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov